The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Thoas Fioretos

Thoas Fioretos

Research team manager

Thoas Fioretos

Trailblazing precision medicine in Europe : A joint view by Genomic Medicine Sweden and the Centers for Personalized Medicine, ZPM, in Germany

Author

  • Albrecht Stenzinger
  • Anders Edsjö
  • Carolin Ploeger
  • Mikaela Friedman
  • Stefan Fröhling
  • Valtteri Wirta
  • Thomas Seufferlein
  • Johan Botling
  • Justus Duyster
  • Michael Akhras
  • Robert Thimme
  • Thoas Fioretos
  • Michael Bitzer
  • Lucia Cavelier
  • Peter Schirmacher
  • Nisar Malek
  • Richard Rosenquist
Show all

Summary, in English

Over the last decades, rapid technological and scientific advances have led to a merge of molecular sciences and clinical medicine, resulting in a better understanding of disease mechanisms and the development of novel therapies that exploit specific molecular lesions or profiles driving disease. Precision oncology is here used as an example, illustrating the potential of precision/personalized medicine that also holds great promise in other medical fields. Real-world implementation can only be achieved by dedicated healthcare connected centers which amass and build up interdisciplinary expertise reflecting the complexity of precision medicine. Networks of such centers are ideally suited for a nation-wide outreach offering access to precision medicine to patients independent of their place of residence. Two of these multicentric initiatives, Genomic Medicine Sweden (GMS) and the Centers for Personalized Medicine (ZPM) initiative in Germany have teamed up to present and share their views on core concepts, potentials, challenges, and future developments in precision medicine. Together with other initiatives worldwide, GMS and ZPM aim at providing a robust and sustainable framework, covering all components from technology development to clinical trials, ethical and legal aspects as well as involvement of all relevant stakeholders, including patients and policymakers in the field.

Department/s

  • Division of Clinical Genetics
  • Translational Genomic and Functional Studies of Leukemia
  • LUCC: Lund University Cancer Centre

Publishing year

2022

Language

English

Pages

242-254

Publication/Series

Seminars in Cancer Biology

Volume

84

Document type

Journal article

Publisher

Academic Press

Topic

  • Cancer and Oncology

Keywords

  • Cancer
  • Clinical trials
  • Molecular profiling
  • Personalized medicine
  • Precision medicine

Status

Published

Research group

  • Translational Genomic and Functional Studies of Leukemia

ISBN/ISSN/Other

  • ISSN: 1044-579X